Alliances
Pfizer and Astellas Pharma announced they have amended the protocols for two Phase III clinical trials, ARCHES and EMBARK, to evaluate Xtandi (enzalutamide) in hormone-sensitive prostate cancer (HSPC). Both trials will wrap sooner than planned as a result.
Cambridge, Mass.-based bluebird bio and Gritstone Oncology inked a deal to combine gene and cell therapies to target cancer. This morning California-based Gritstone said it will leverage its artificial intelligence platform, dubbed EDGE, to analyze specific tumor types for the collaboration.
Madison, Wisconsin-based EXACT Sciences stocks climbed as much as 21 percent in premarket trading in response to a deal with Pfizer to co-market Exact’s Cologuard non-invasive colon cancer test.
Months after partnering with Sanofi on infectious diseases, Germany-based Evotec has formed another significant partnership with Novo Nordisk. The two companies will combine their forces to develop treatments for diabetes, nonalcoholic steatohepatitis (NASH) and other diseases.
Vancouver, British Columbia-based Sierra Oncology acquired momelotinib from Gilead Sciences in a deal that could hit $198 million.
Chicago-based AbbVie has exercised its exclusive license option to develop and commercialize Belgium-based Argenx’s ARGX-115. The compound is an antibody that targets novel immuno-oncology target glycoprotein A repetitions predominant (GARP).
Harbour BioMed signed an exclusive strategic partnership deal with Sichuan Kelun-Biotech Biopharmaceutical Co. to develop and commercialize an anti-PD-L1 antibody, A167, currently in Phase II development.
BioNTech, headquartered in Mainz, Germany, and Pfizer, based in New York City, signed a multi-year research-and-development deal to develop mRNA-based flu vaccines.
Regeneron’s fasinumab hit the mark in a late-stage study assessing patients with chronic pain from osteoarthritis (OA) of the knee or hip. At 16 weeks patients experienced significantly less pain and also showed significantly improved functional ability from baseline.
RXi Pharmaceuticals, headquartered in Marlborough, Mass., signed a research collaboration deal with Sweden’s Karolinska Institute. They will work to develop cancer therapies using RXi’s sd-rxRNA compounds against targets involved in T-cell and NK cell differentiation.
PRESS RELEASES